JKJoseph Kirk

Joseph Kirk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joseph Kirk has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human-relevant near-organ neuromodulation of the immune system via the splenic nerve

    by Matteo Donegà, Cathrine T. Fjordbakk, Joseph Kirk, David M. Sokal, Isha Gupta, Gerald E. Hunsberger, Abbe Crawford, Simon Cook, Jaime Viscasillas, Thaleia-Rengina Stathopoulou, et al.

    Significance: Bioelectronic modulation of the autonomic nervous system innervating the spleen represents a new therapeutic avenue. Studies in rodents suffer from the limitation that stimulation parameters and anatomy are not directly applicable to humans. This work demonstrates the translation of biological mechanisms in a large animal model with similar anatomical, histological, and functional characteristics for derivation of human-relevant parameters. Here, we show the scientific process for translating a bioelectronic medicine to clinical readiness. The results presented can be used in three ways: 1) as a system to demonstrate the species translation of neuroimmune modulation, 2) as an exemplar of how translational models can reveal additional potential mechanisms, and 3) as a general methodology to determine human-relevant stimulation parameters.


  • Open Access

    Splenic Nerve Neuromodulation Reduces Inflammation and Promotes Resolution in Chronically Implanted Pigs

    by David M. Sokal, Alex McSloy, Matteo Donegà, Joseph Kirk, Romain A. Colas, Nikola Dolezalova, Esteban A. Gomez, Isha Gupta, Cathrine T. Fjordbakk, Sebastien Ouchouche, et al.

    Neuromodulation of the immune system has been proposed as a novel therapeutic strategy for the treatment of inflammatory conditions. We recently demonstrated that stimulation of near-organ autonomic nerves to the spleen can be harnessed to modulate the inflammatory response in an anesthetized pig model. The development of neuromodulation therapy for the clinic requires chronic efficacy and safety testing in a large animal model. This manuscript describes the effects of longitudinal conscious splenic nerve neuromodulation in chronically-implanted pigs. Firstly, clinically-relevant stimulation parameters were refined to efficiently activate the splenic nerve while reducing changes in cardiovascular parameters. Subsequently, pigs were implanted with a circumferential cuff electrode around the splenic neurovascular bundle connected to an implantable pulse generator, using a minimally-invasive laparoscopic procedure. Tolerability of stimulation was demonstrated in freely-behaving pigs using the refined stimulation parameters. Longitudinal stimulation significantly reduced circulating tumor necrosis factor alpha levels induced by systemic endotoxemia. This effect was accompanied by reduced peripheral monocytopenia as well as a lower systemic accumulation of CD16+CD14highpro-inflammatory monocytes. Further, lipid mediator profiling analysis demonstrated an increased concentration of specialized pro-resolving mediators in peripheral plasma of stimulated animals, with a concomitant reduction of pro-inflammatory eicosanoids including prostaglandins. Terminal electrophysiological and physiological measurements and histopathological assessment demonstrated integrity of the splenic nerves up to 70 days post implantation. These chronic translational experiments demonstrate that daily splenic nerve neuromodulation,viaimplanted electronics and clinically-relevant stimulation parameters, is well tolerated and is able to prime the immune system toward a less inflammatory, pro-resolving phenotype.